CRSP
Crispr Therapeutics AG
58.30$
+3.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +10,340.3% | +116.4% | -21.3% | +80.2% | +118.1% | +71.4% | +50.5% | -18.5% | -0.6% | +0.6% | +1.0% | |
| – | +16,102.5% | +104.1% | -22.4% | +87.8% | +111.7% | +73.8% | +40.8% | -23.3% | +3.0% | +1.5% | +2.5% | |
| – | +16,403.8% | +102.3% | -24.0% | +90.5% | +106.7% | +23.8% | -21.0% | -77.0% | +83.8% | -23.4% | +19.1% | |
| – | +16,403.8% | +102.3% | -24.0% | +90.5% | +106.7% | +79.1% | +40.7% | -23.7% | -6.7% | +12.4% | +3.8% | |
| – | -88.7% | +831.3% | -16.8% | -96.6% | +12.5% | +10,853.5% | -97.2% | +3,572.1% | +1,685.7% | -87.5% | -100.0% | |
| – | – | -100.0% | – | +0.0% | +0.0% | – | – | – | – | – | – | |
| – | – | +1,483.4% | -10.3% | -1.9% | +293.7% | -42.1% | +226.3% | +18.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -10.8% | -12.1% | -13.8% | -16.0% | -18.7% | -23.4% | -30.6% | -43.2% | -77.5% | – | – | |
| – | +2,117.9% | -40.5% | -25.5% | +15.9% | +31.5% | +28.6% | +115.2% | +4.3% | -5.7% | -10.6% | +10.8% | |
| – | +373.2% | +116.6% | -34.0% | +91.2% | +105.8% | +65.1% | +27.2% | +1.0% | -10.2% | -19.3% | +69.9% | |
| – | +0.9% | +57.2% | -26.7% | -20.1% | -76.0% | +33.8% | +7.0% | +30.3% | -1.4% | +10.6% | +7.5% | |
| – | +650.7% | +188.4% | -64.1% | +209.3% | +17.3% | +53.0% | +62.9% | +85.1% | +39.1% | -61.4% | -24.3% | |
| – | +0.9% | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | -19.3% | +108.8% | +139.5% | +77.2% | +44.2% | -21.8% | +0.4% | +2.6% | -0.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -58.2% | +226.8% | +19.7% | +18.7% | +15.8% | +21.9% | -3.3% | +1.9% | +6.5% | +6.6% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.